High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant.

William C Shropshire,Bradley T Endres,Jovan Borjan,Samuel L Aitken,William C Bachman,Christi L McElheny,Chin-Ting Wu,Stephanie L Egge,Ayesha Khan,William R Miller,Micah M Bhatti,Pranoti Saharasbhojane,Akito Kawai,Ryan K Shields,Samuel A Shelburne,Yohei Doi

The Journal of antimicrobial chemotherapy（2023）

引用 0|浏览16

暂无评分

摘要

We identified ceftazidime/avibactam resistance in E. coli associated with a novel CMY variant. Unlike other AmpC enzymes, CMY-185 appears to require an additional substitution on top of N346Y to confer ceftazidime/avibactam resistance.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要